External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds
Ellen Bellon, Marjolijn J. L. Ligtenberg, Sabine Tejpar et al. · The Oncologist · 2011
Abstract Learning Objectives After completing this course, the reader will be able to: Identify the most frequent errors made in KRAS testing in this study and the possible consequences for a patient.Describe factors that could increase the chance of an error during KRAS testing. This article is available for continuing medical education credit at CME.TheOncologist.com The use of epidermal growth factor receptor–targeting antibodies in metastatic colorectal cancer has been restricted to patients with wild-type KRAS tumors by the European Medicines Agency since 2008, based on data showing a lack of efficacy and potential harm in patients with mutant KRAS tumors. In an effort to ensure optimal, uniform, and reliable community-based KRAS testing throughout Europe, a KRAS external quality assessment (EQA) scheme was set up. The first large assessment round included 59 laboratories from eight different European countries. For each country, one regional scheme organizer prepared and distributed the samples for the participants of their own country. The samples included unstained sections of 10 invasive colorectal carcinomas with known KRAS mutation status. The samples were centrally validated by one of two reference laboratories. The laboratories were allowed to use their own preferred method for histological evaluation, DNA isolation, and mutation analysis. In this study, we analyze the setup of the KRAS scheme. We analyzed the advantages and disadvantages of the regional scheme organization by analyzing the outcome of genotyping results, analysis of tumor percentage, and written reports. We conclude that only 70% of laboratories correctly identified the KRAS mutational status in all samples. Both the false-positive and false-negative results observed negatively affect patient care. Reports of the KRAS test results often lacked essential information. We aim to further expand this program to more laboratories to provide a robust estimate of the quality of KRAS testing in Europe, and provide the basis for remedial measures and harmonization.
Cited by 83 works. doi:10.1634/theoncologist.2010-0429 Open-access PDF
Authors
- Ellen Bellon
- Marjolijn J. L. Ligtenberg
- Sabine Tejpar
- Gert D. Hertogh
- Karin de Stricker
- Anders Edsjö
- Vassilis G. Gorgoulis
- Gerald Höfler
- Andreas Jung
- Athanassios Kotsinas
- Pierre Laurent‐Puig
- Fernando López‐Ríos
- Tine Plato Hansen
- Étienne Rouleau
- Peter Vandenberghe
- J. Han van Krieken
- Elisabeth M. C. Dequeker
References
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
- Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing
- Clinical Laboratory Reports in Molecular Pathology
- Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations
- Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.